Nikolay Markov
Has grant
Research Scholar
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Machine learning approaches to predict outcomes and complications in ICU patients
Open Date: 2024-01-01
Close Date: 2025-12-31
Articles (17)
Year:
2025
Year:
2025
Year:
2025
Background Critically ill patients who develop invasive pulmonary aspergillosis (IPA) have high mortality rates despite antifungal therapy. Diagnosis is difficult in these patients and incidences vary in the literature. Bronchoalveolar lavage (BAL) fluid galactomannan (GM) is a helpful marker, although the optimal cutoff is unclear. Methods This was a single-center cohort study of patients requiring mechanical ventilation in the medical intensive care unit (ICU) from June 2018 to March 2023. Demographics, BAL, and outcome data were extracted from the electronic health record and compared between groups of patients who grew Aspergillus from BAL, those who had elevated BAL GM levels (>0.5, >0.8, or >1.0) but did not grow Aspergillus, and those with neither. Results Of >1700 BALs from 688 patients, only 18 BALs from 15 patients grew Aspergillus. Patients who grew Aspergillus had more intubated days (29 vs 11, P = .002) and more ICU days (34 vs 15, P = .002). BAL GM level was higher from samples that grew Aspergillus than those that did not (median optical density index: 7.08 vs 0.11, P < .001). Conclusions In this large cohort of critically ill patients, we found a low rate of Aspergillus growth and variable BAL GM elevation. These data suggest that the pretest probability of IPA should be considered low in a general ICU population undergoing BAL evaluation to define the etiology of pneumonia. Elevated BAL GM may not reliably indicate invasive disease, but lack of culture positivity may also miss true infection. Improved scoring systems are needed to enhance pretest probability for diagnostic test stewardship purposes, and tests must be interpreted in their own clinical contexts.
Year:
2025
Interstitial lung disease (ILD) is present in over 60% of patients with systemic sclerosis (SSc) and is the leading cause of SSc-related deaths. Profibrotic monocyte-derived alveolar macrophages (MoAM) play a causal role in the pathogenesis of pulmonary fibrosis in animal models where their persistence in the niche requires signaling through Colony Stimulating Factor 1 Receptor (CSF1R). We hypothesized that the presence and proportion of MoAM in bronchoalveolar lavage (BAL) fluid from patients with SSc-ILD may be a biomarker of ILD severity. To test this hypothesis, we analyzed BAL fluid from 9 prospectively enrolled patients with SSc-ILD and 13 healthy controls using flow cytometry and single-cell RNA sequencing. Patients with SSc-ILD had more MoAM and interstitial macrophages in BAL fluid than healthy controls, and their abundance was associated with lung fibrosis severity. We identified changes in the MoAM transcriptome as a function of treatment with mycophenolate, an effective therapy for SSc-ILD. In SSc-ILD lung explants, spatial transcriptomics identified an expanded population of interstitial macrophages spilling into the alveolar space. Our findings suggest that the proportion of profibrotic MoAM and interstitial macrophages in BAL fluid may serve as a biomarker of SSc-ILD and credential them as possible targets for therapy.
Year:
2025
Severe community-acquired pneumonia (CAP) remains a major cause of critical illness, yet there are no validated early clinical criteria to predict short-term treatment outcomes in these patients. Short-term pneumonia treatment outcomes are less affected by confounding factors introduced by a prolonged hospital course, and early prediction of short-term treatment outcomes can help physicians identify those who are likely to fail the current treatment and implement adjustments to existing diagnostic and therapeutic plans. Traditional clinical stability criteria such as Halm’s criteria are not calibrated for early outcome prediction in critically ill severe pneumonia patients. We applied the XGBoost algorithm to predict pneumonia cure by day 7-8 post- intubation with clinical features from days 1-3 in mechanically ventilated patients with severe CAP from the Successful Clinical Response in Pneumonia Therapy (SCRIPT) study, a prospective cohort study at a tertiary academic center. Pneumonia episodes were adjudicated for day 7-8 cure status by a panel of critical care physicians using a structured review process. Clinical features that inform Halm’s criteria, including vital signs, oxygenation parameters, mental status, and vasopressor use, were extracted from the electronic health record. We also examined model performance by including additional features, such as laboratory data, ventilator settings, and medications. Basic demographic characteristics including age and BMI were also incorporated. Among 85 patients, 42 (49.4%) were cured by day 7–8. The best-performing model, which used Halm’s clinical features and ventilator features from days 1–3, achieved a cross-validated AUROC of 0.757. Inclusion of lab and medication data did not significantly improve performance. Key predictors included GCS, norepinephrine requirement, and BMI. We prove the feasibility of using ML models to predict short-term treatment outcomes of severe CAP among critically ill patients with basic clinical features. Future studies should focus on external validation and clinical integration to inform prognosis and early reevaluation of treatment strategy in patients with predicted poor outcomes.
Year:
2025
Background Interstitial lung disease (ILD) affects > 40% of patients with systemic sclerosis (SSc/scleroderma) and is the leading cause of disease-related mortality. Although therapies may slow progression, outcomes remain poor, partly because ILD is often detected after irreversible lung injury has occurred. Although chest computed tomography (CT) is a sensitive tool for ILD detection and is recommended at SSc diagnosis, it is oftentimes not performed and even less often performed serially. We sought to develop tools to predict ILD and mortality in patients with SSc using data routinely available in the electronic health record (EHR) to inform medical decision-making. Methods We analyzed longitudinal EHR data from two SSc cohorts: Northwestern University (1,169 participants; derivation cohort) and Yale University (376 participants; validation cohort). We identified clinical features from existing cohort-linked EHR queries composing a convenience sample of data from participants spanning decades rather than employing a single unified data collection effort. Three ILD experts independently reviewed CT reports and classified each as having or lacking ILD. To explore derivation cohort data structure, patients with > =3 forced vital capacity (FVC) results available were identified and stratified according to prevalent or absent ILD. Using unsupervised trajectory-based clustering exploratory analyses, we determined standardized patterns across groups. ML models were then developed using clinical EHR data as predictor variables and prevalent ILD and all-cause mortality as outcome variables. Model performance was assessed using area under the receiver operating characteristic curve (AUC). Results Seventy-four clinical features with low missingness, including demographic, vital sign, laboratory, and pulmonary function test data, were utilized for analyses. Four robust PFT trajectory clusters were identified that were associated with ILD prevalence and mortality in exploratory analyses. A ML model for ILD detection achieved an AUC of 0.832 and retained performance in the Yale cohort (AUC 0.754). In addition to established predictors such as autoantibodies and pulmonary function, the model identified routine laboratory measurements, including red cell distribution width (RDW), white blood cell count, and serum chloride, as important contributors. One-year mortality prediction achieved AUCs of 0.904 in the North-western cohort and 0.910 in the Yale cohort. Among patients with SSc-ILD, one-year mortality was predicted with AUCs of 0.744 and 0.902 in the Northwestern and Yale cohorts, respectively. Unexpectedly, we found that subtle laboratory abnormalities (such as change in RDW) contributed to predicting mortality. Conclusions Our prediction models comprised of widely available EHR data are useful tools to identify SSc patients at high risk for prevalent ILD and all-cause mortality. Integration of these models into clinical practice could enable scalable risk stratification and inform individualized ILD screening and monitoring strategies for SSc patients.
Year:
2025
Year:
2024
Year:
2024
Lung transplantation is a life-saving therapy for end-stage lung disease but has the poorest survival among solid organ transplants. We analyzed standardized electronic health record (EHR) data from the United Network for Organ Sharing (UNOS) to predict one-, three-, and five-year survival and favorable long-term outcomes post-lung transplant. We applied two multivariate machine learning approaches, XGBoost or a tabular BERT model called EHRFormer, to data from 43,869 first-time lung transplant recipients (1987–2022). XGBoost and EHRFormer identified features that align closely with established risk factors for worse outcomes such as length of index stay, recipient age, and creatinine at the time of transplant. We developed a simple perturbation method with EHRFormer to probe in silico multivariate interactions between features that influence model prediction. Despite their attention to known risk factors, machine learning applied to EHR data collected by UNOS poorly predict one-, three-, and five-year mortality after lung transplant.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (44)
Duncan Moore
Rheumatologist and Assistant Professor of Medicine
Northwestern Memorial Hospital
Catherine Myers
Assistant Professor of Medicine
Northwestern University Feinberg School of Medicine
Yvan Saeys
department of social work and social pedagogy ghent university ghent belgium
Luke Rasmussen
Northwestern University
Changwan Ryu
Assistant Professor
Yale University
Manu Jain
Northwestern University
Anthony Esposito
Assistant Professor
Northwestern University Feinberg School of Medicine
Yuan Luo
Chief AI Officer and Associate Professor
Northwestern University
Ankit Agrawal
Research Professor
Northwestern University
Martijn Nawijn
Professor in functional genetics of chronic respiratory disease
University Medical Center Groningen
Nandita Nadig
Assistant Professor
Northwestern University Feinberg School of Medicine
Rosemary Braun
Associate Professor
Northwestern University
Luisa Morales-Nebreda
Northwestern University
Ziyou Ren
Assistant Professor
Northwestern University Feinberg School of Medicine
Kaylee Worlock
University College London
Matthew Dapas
Research Assistant Professor
Northwestern University
Robert Tighe
Associate Professor
Duke Medicine
Frederick M. Howard
-
James Walter
Assistant Professor
Northwestern Memorial Hospital
Alexander Misharin
Associate Professor
Northwestern University Feinberg School of Medicine
Thomas Stoeger
Assistant Professor
Northwestern University
Dana Pe'er
Sloan Kettering Institute
Richard G. Wunderink
Northwestern University Feinberg School of Medicine
GR Scott Budinger
Professor of Medicine
Northwestern University
Peter Sporn
Professor of Medicine
Northwestern University Feinberg School of Medicine
Krishnan Warrior
Assistant Professor of Medicine
Northwestern Medicine
Christophe Bécavin
Assitant Professor/Enseignant-Chercheur
Université Côte d'Azur
Cara Gottardi
Professor
Northwestern University Feinberg School of Medicine
MINZHE GUO
Assistant Professor
Cincinnati Children's Hospital Medical Center
Vishu Gupta
Princeton University
Chitaru Kurihara
-
Vikas Mehta
Attending Pathologist
Northwestern Medicine
Monique Hinchcliff
Associate Professor
Yale University
Hiam Abdala Valencia
Associate Professor
Northwestern University
Catherine A Gao
Northwestern Medicine
Angela Christine Argento
MD/Assistant Professor of Medicine
Northwestern University Feinberg School of Medicine
Benjamin Singer
Vice Chair for Research, Department of Medicine; Lawrence Hicks Professor of Pulmonary Medicine; Associate Professor of Medicine & Biochemistry and Molecular Genetics
Northwestern University Feinberg School of Medicine
Malte D Luecken
Principal Investigator
Helmholtz Zentrum München Deutsches Forschungszentrum für Umwelt und Gesundheit
Wouter Saelens
EPFL (École Polytechnique Fédérale de Lausanne)
Chuan Xu
University of Cambridge
Ewa Szczurek
Director
University of Warsaw
Gorkem Durak
Clinical Research Associate / Scientific Researcher
Northwestern Medicine
Nikita Joshi
Northwestern University
John Martin Coleman III
Associate Professor
Northwestern University Feinberg School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.